CJ - 13610, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

CJ-13610 may be used to study 5-lipoxygenase-mediated cell signaling.

Biochem/physiol Actions

CJ-13610 inhibits the biosynthesis of leukotriene B4 and regulates the IL-6 mRNA expression in macrophages. It reduces fibrosis and necroinflammation of liver in carbon tetrachloride-treated mice.

CJ-13,610 is a potent inhbititor of 5-lipoxygenase (5-LO) activity (IC₅₀ = 70 nM).

Features and Benefits

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle